SpringWorks Therapeutics Inc. has a potentially significant market opportunity with positive data in hand from its Phase IIb ReNeu trial of mirdametinib in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), compared with existing options that are only available for pediatric patients.
SpringWorks announced the results of the trial on 16 November, stating that it plans to seek US Food and Drug...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)